$FRX News

Last published 5y ago

5y agoFRXThe Beachbody Company and Myx Fitness Complete Merger with Forest Road Acquisition Corp., Creating the Leading Subscription Health and Wellness Company for the Mass MarketBusiness WireThe Beachbody Company Group, LLC ("Beachbody") today announced the three-way business combination with Myx Fitness Holdings, LLC ("Myx") and Forest Road Acquisition Corp. (NYSE:FRX) ("Forest Road") was completed on June 25, 2021, creating the leading s
5y agoFRXForest Road Acquisition Corp. Stockholders Approve Proposed Merger With The Beachbody Company and Myx Fitness, Creating the Leading Subscription Health and Wellness Company for the Mass MarketBusiness WireForest Road Acquisition Corp. (NYSE:FRX) ("Forest Road") today announced that its stockholders have voted to approve the proposed three-way business combination (the "Business Combination") with The Beachbody Company Group, LLC ("Beachbody") and Myx Fit
5y agoFRXForest Road Acquisition Corp., The Beachbody Company and Myx Fitness Announce Expected Closing of Business CombinationBusiness WireThe proposed business combination is expected to close on Friday, June 25, 2021, assuming Forest Road receives stockholder approval at the Special Meeting of Stockholders to be held on June 24, 2021 Following closing, the combined company's stock
5y agoFRXThe Beachbody Company Leads Investment in Feed Media Group, Premier B2B Music Licensing PlatformBusiness WireFeed Media Group's service provides enhanced licensed music content and economics Strengthens Beachbody's position as innovative leader in at-home fitness The Beachbody Company Group, LLC ("Beachbody"), a leader in subscription health and wellness
5y agoFRXBeachbody CEO Letter to Forest Road ShareholdersBusiness WireThe Beachbody Company, LLC: Dear Forest Road Acquisition Corp. shareholders, More than 22 years ago, I asked Jon Congdon if he would join me in creating a company that would take advantage of the growth in direct-to-consumer marketing and the inte
5y agoFRXThe Beachbody Company to Participate in Baird's 2021 Global Consumer, Technology & Services ConferenceBusiness WireThe Beachbody Company, LLC ("Beachbody"), a leading subscription health and wellness company, today announced that Beachbody's management team is participating in the Baird 2021 Global Consumer, Technology & Services Conference on Tuesday, June 8, 2021.
5y agoFRXForest Road Letter to StockholdersBusiness WireDear Forest Road Acquisition Corp. Stockholders, On June 24, 2021, Forest Road Acquisition Corp. (NYSE:FRX) ("Forest Road") will host a special meeting of stockholders to vote on its proposed merger with The Beachbody Company Group, LLC ("Beachbody"
5y agoFRXForest Road Acquisition Corp. Announces Effectiveness of Registration Statement and Special Meeting Date for Proposed Business Combination with The Beachbody Company and Myx FitnessBusiness WireForest Road Acquisition Corp. (NYSE:FRX) ("Forest Road"), today announced that the U.S. Securities and Exchange Commission ("SEC") has declared effective its Registration Statement on Form S-4 (as amended, the "Registration Statement"), which includes a
5y agoFRXForest Road Acquisition Corp. and The Beachbody Company Announce Combined First Quarter 2021 Financial Results for Beachbody and MyxBusiness WireStrong First Quarter Revenue Growth, Record Engagement Levels Poised to Accelerate Growth Upon Completion of Proposed Three-Way Merger Forest Road Acquisition Corp. (NYSE:FRX) ("FRX" or "Forest Road") and The Beachbody Company Group, LLC ("Beachbo
5y agoFRXThe Beachbody Company Announces BODi: A New Interactive Premium Tier for Beachbody on Demand; Underpinned by Partnership with Feed.fmBusiness WireBODi combines the immersive, personalized experience of in-person classes with the convenience of at-home workouts Partnership with Feed.fm provides access to deep music library of popular artists, enabling curation and delivery of engaging musi
5y agoFRXThe Beachbody Company to Participate in 16th Annual Needham Virtual Technology & Media ConferenceBusiness WireThe Beachbody Company, LLC ("Beachbody"), a leading subscription health and wellness company, today announced that the Beachbody's management team is participating in the 16th Annual Needham Virtual Technology & Media Conference on Wednesday, May 19, 20
5y agoFRXThe Beachbody Company and Forest Road Acquisition Corp to Participate in SPACInsider WebinarBusiness WireThe Beachbody Company, LLC ("The Beachbody Company,"), and Forest Road Acquisition Corp. (NYSE:FRX) ("Forest Road"), a publicly-traded special purpose acquisition corporation, today announced that the two companies will participate in a webinar hosted b
5y agoDIS FRX MSFT ORCL+7Kevin Mayer talks about his disappointing departures at Disney and TikTok, and the long decline of pay TVCNBCKevin Mayer gets real with why he left Disney, how he got a raw deal at TikTok, and why he's excited about DAZN's global prospects.
5y agoBX FRX DISFormer Disney Executives Turn Into L.A.’s Hottest DealmakersBloombergKevin Mayer and Tom Staggs, who were both once in line to lead Walt Disney Co., are emerging as two of the busiest dealmakers in Los Angeles.
5y agoSYNC NEBC FRX CMLFMoore Kuehn Encourages SYNC, NEBC, FRX, and CMLF Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
5y agoFRXThe Beachbody Company, a Leader in Digital Fitness Streaming and Nutrition Solutions, to Become Publicly Traded CompanyBusiness WireSANTA MONICA, Calif. & NEW YORK--(BUSINESS WIRE)--The Beachbody Company Group, LLC (“The Beachbody Company,” “Beachbody” or “the Company”) announced today its intention to become a public company by entering into a definitive three-way merger agreement with Forest Road Acquisition Corp. (NYSE: FRX) (“Forest Road”), a publicly traded special purpose acquisition company, and Myx Fitness Holdings, LL ...
5y agoFRXForest Road Acquisition Corp. Announces Separate Trading of Its Class A Common Stock and Warrants, Commencing January 15, 2021Business WireNEW YORK--(BUSINESS WIRE)--Forest Road Acquisition Corp. (NYSE: FRX.U) (the “Company”) announced today that, commencing January 15, 2021, holders of the 30,000,000 units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units. The shares of Class A common stock and warrants that are separated will t ...
5y agoFRXForest Road Acquisition Corp. Announces Closing of Upsized $300,000,000 Initial Public OfferingBusiness WireNEW YORK--(BUSINESS WIRE)--Forest Road Acquisition Corp. (the “Company”) announced today the closing of its upsized initial public offering of 30,000,000 units at a price to the public of $10.00 per unit, which includes an exercise of the underwriters' option to purchase 3,900,000 additional units. The offering resulted in gross proceeds to the Company of $300 million.
5y agoFRXForest Road Acquisition Corp. Announces Pricing of Upsized $261 Million Initial Public OfferingBusiness WireLOS ANGELES--(BUSINESS WIRE)--Forest Road Acquisition Corp. (the “Company”), a newly incorporated blank check company, today announced the pricing of its upsized initial public offering of 26,100,000 units at a price of $10.00 per unit. The units are expected to be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “FRX.U” beginning November 25, 2020. Each unit co ...
12y agoACT FRXActavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of ForestBusiness WireDUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis’ proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest’s agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products ...
12y agoACT FRXActavis and Forest Announce Preliminary Stockholder Merger Consideration Election ResultsBusiness WireDUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis’ pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions ...
12y agoACT FRXActavis and Forest Announce Tentative Election Deadline of June 27, 2014Business WireDUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis’ planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the “Election Deadline”). The Election Deadline may be extended, in which case ...
12y agoACT FRXActavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and DevelopmentBusiness WireDUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that C. David Nicholson, PhD will be appointed Senior Vice President, Actavis Global Brands R&D following the close of Actavis’ planned acquisition of Forest. In this role, Dr. Nicholson will lead the global teams focused on developing Actavis’ significantly expanded branded R&D port ...
12y agoACT FRXActavis and Forest Shareholders Approve Proposals Related to Actavis’ Planned Acquisition of ForestBusiness WireDUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis’ planned acquisition of Forest were approved by both Actavis’ and Forest’s shareholders.
12y agoACT FRXActavis and Forest Announce Effectiveness of Registration Statement on Form S-4Business WireDUBLIN, Ireland and NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission (“SEC”) by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the “Form S-4”), which includes a joint proxy statement of Actavis and Forest, was declared effective on ...
12y agoIRWD FRXIronwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014Business WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2014 in Chicago, May 3 through May 6, 2014. The data will be presented through the following poster presentations:
12y agoFURX FRXLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Furiex Pharmaceuticals, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (NASDAQ:FURX) concerning the proposed acquisition of the Company by Forest Laboratories, Inc. (“Forest”) (NYSE:FRX). Under the terms of the definitive merger agreement, Furiex stockholders will receive $95 per share in cash and ...
12y agoFURX FRXNewman Ferrara LLP Announces Investigation of Furiex Pharmaceuticals, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP is investigating potential claims against the board of directors of Furiex Pharmaceuticals, Inc. (“Furiex”) (Nasdaq:FURX) concerning the proposed sale of Furiex to Forest Laboratories Inc. (“Forest”) (NYSE:FRX).
12y agoFRX FURXForest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI)Business WireNEW YORK & MORRISVILLE, N.C.--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) and Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent ...
12y agoACT FRXActavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-RodinoBusiness WireDUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis’ pending acquisition of Forest. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Ac ...
12y agoIRWD FRXIronwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS®Business WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS® (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campa ...
13y agoFRXForest Laboratories and Almirall Decide to Delay NDA Filing for Aclidinium/formoterol CombinationBusiness WireNEW YORK & BARCELONA, Spain--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM:MC) today announced that they will delay the planned Q4 2013 submission of a New Drug Application (NDA) for the combination of aclidinium bromide, a long acting muscarinic antagonist and formoterol fumarate, a long acting beta agonist, for the indication of Chronic Obstructive Pulmonary Dise ...
13y agoIRWD FRXIronwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013Business WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2013 in Orlando, Fla., May 18 through May 21, 2013. Among the data highlighted will be two oral presentations: one providing insight into the GC-C/cGMP pathway in patients with ...
13y agoIRWD FRXIronwood and Forest Announce U.S. Availability of LINZESS™ (Linaclotide)Business WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today that LINZESS™ (linaclotide) is now available in pharmacies throughout the United States. The U.S. Food and Drug Administration (FDA) recently approved LINZESS as a once-daily oral capsule for adult men and women suffering from irritable bowel syndrom ...
14y agoIRWD FRXADDING MULTIMEDIA Ironwood and Forest Announce FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic ConstipationBusiness WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today that LINZESS™ (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
14y agoIRWD FRXIronwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic ConstipationBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) will be hosting a conference call to discuss the U.S. Food and Drug Administration (FDA) approval of LINZESS™ at 4:00 p.m. Eastern Time on Thursday, August 30, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8 ...
14y agoIRWD FRXIronwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012Business WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster presentations during Digestive Disease Week (DDW) 2012 being held in San Diego, May 19 through May 22, 2012. Linaclotide is an investigational guanylate cyclase type-C ...
14y agoIRWD FRXIronwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012Business WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syn ...
15y agoIRWD FRXIronwood and Forest to Present Linaclotide Results from Phase 2B and Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation or Chronic ConstipationBusiness WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting additional linaclotide results from four pivotal Phase 3 trials and one Phase 2b study in patients with either irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC) at the American College of Gastroen ...
15y agoIRWD FRXIronwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA ReviewBusiness WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). With a standard 10-month re ...
15y agoIRWD FRXIronwood and Forest Announce Submission of New Drug Application for Linaclotide for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic ConstipationBusiness WireCAMBRIDGE, Mass. and NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for linaclotide, a guanylate cyclase type-C (GC-C) agonist, for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic ...
15y agoMRK FRXDr. Ashok Amin Joins Advaxis as Vice President of Research and DevelopmentBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has appointed Dr. Ashok Amin as Vice President of Research and Development.
15y agoIRWD FRXIronwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with ConstipationBusiness WireCAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with irritable bowel syndrome with constipation (IBS-C) during the 2011 Digestive Disease Week (DDW) annual meeting that will be held in Chicago from May 7 through M ...
15y agoFRX CLDAForest Laboratories Completes Acquisition of Clinical Data, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that it has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) (“Clinical Data”) by means of what is known as a short-form merger under Delaware law.
15y agoCLDA FRXThe Law Offices of Vincent Wong Announce an Investigation into Possible Breaches of Fiduciary Duty by the Board of Clinical Data, Inc. in Connection with the Sale of the Company to Forest Laboratories, Inc. – CLDABusiness WireNEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating the Board of Directors of Clinical Data, Inc. (Nasdaq: CLDA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. (NYSE: FRX). Under the terms of the transaction, Clinical Data shareholders will receive $30.00 per share in cash, w ...
15y agoCLDA FRXBrower Piven Announces an Investigation of the Acquisition of Clinical Data, Inc. by Forest Laboratories, Inc.Business WireSTEVENSON, Md.--(BUSINESS WIRE)--The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Clinical Data, Inc. (“Clinical Data”) (NASDAQ:CLDA) and other violations of state law by the Board of Directors of Clinical Data relating to the proposed acquisition of the company by Forest Laboratories, Inc. ...
15y agoCLDA FRXThe Law Office of Abe Shainberg Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Clinical Data, Inc. in Connection with the Sale of the Company to Forest Laboratories, Inc. – CLDABusiness WireNEW YORK--(BUSINESS WIRE)--The Law Office of Abe Shainberg is investigating the Board of Directors of Clinical Data, Inc. (Nasdaq: CLDA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. (NYSE: FRX). Under the terms of the transaction, Clinical Data shareholders will receive $30.00 per share in cash, wi ...
15y agoCLDA FRXRobbins Umeda LLP Is Investigating Clinical Data, Inc. Acquisition for ShareholdersBusiness WireSAN DIEGO--(BUSINESS WIRE)--Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Clinical Data, Inc. (NASDAQ: CLDA) in connection with their efforts to sell the company to Forest Laboratories, Inc. (NYSE: FRX). Under the proposed agreement, Forest La ...
15y agoCLDA FRXRigrodsky & Long, P.A. Investigates Buyout of Clinical Data, Inc. - CLDABusiness WireWILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Clinical Data, Inc. (“Clinical Data” or the “Company”) (Nasdaq: CLDA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Forest Laboratories, Inc. (“Forest Labs”) (N ...
15y agoFRX CLDAForest Laboratories to Acquire Clinical Data, Inc.Business WireNEW YORK & NEWTON, Mass.--(BUSINESS WIRE)--Forest Laboratories, Inc. (Forest) (NYSE: FRX) and Clinical Data, Inc. (Clinical Data) (NASDAQ: CLDA) today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 pe ...